S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
NASDAQ:ATXS

Astria Therapeutics (ATXS) Stock Price, News & Analysis

$7.68
-0.38 (-4.71%)
(As of 12/29/2023 ET)
Today's Range
$7.67
$8.12
50-Day Range
$4.42
$8.06
52-Week Range
$4.26
$16.28
Volume
257,105 shs
Average Volume
750,008 shs
Market Capitalization
$278.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.75

Astria Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
157.2% Upside
$19.75 Price Target
Short Interest
Healthy
2.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Astria Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$11.58 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.28) to ($2.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

292nd out of 950 stocks

Pharmaceutical Preparations Industry

139th out of 442 stocks


ATXS stock logo

About Astria Therapeutics Stock (NASDAQ:ATXS)

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

ATXS Stock Price History

ATXS Stock News Headlines

New Year's Sale: Get 12 Months of Stock Picks for $9.00
Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this.
New Year's Sale: Get 12 Months of Stock Picks for $9.00
Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this.
Astria Therapeutics Presents Potential For STAR-0125 To Prevent HAE
Earnings Preview For Astria Therapeutics
Expert Ratings for Astria Therapeutics
See More Headlines
Receive ATXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATXS
Employees
45
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$19.75
High Stock Price Target
$25.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+157.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-51,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.54 per share

Miscellaneous

Free Float
35,062,000
Market Cap
$278.78 million
Optionable
Not Optionable
Beta
0.84

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Ms. Jill C. Milne Ph.D. (Age 55)
    Co-Founder, CEO, President & Director
    Comp: $928.52k
  • Mr. Benjamin S. Harshbarger J.D. (Age 54)
    Chief Legal Officer
    Comp: $621.91k
  • Mr. Noah Clauser CPA (Age 49)
    CFO & Treasurer
    Comp: $508.79k
  • Ms. Keri McGrail
    Senior Vice President of Human Resources
  • Ms. Andrea L. Matthews
    Chief Business Officer
  • Mr. Andrew A. KomjathyMr. Andrew A. Komjathy (Age 59)
    Chief Commercial Officer
  • Dr. Christopher J. Morabito M.D. (Age 53)
    Chief Medical Officer
  • Mr. John Ruesch
    Senior Vice President of Pharmaceutical Sciences & Technical Operations














ATXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Astria Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXS shares.
View ATXS analyst ratings
or view top-rated stocks.

What is Astria Therapeutics' stock price target for 2024?

4 equities research analysts have issued twelve-month price targets for Astria Therapeutics' stock. Their ATXS share price targets range from $18.00 to $25.00. On average, they predict the company's share price to reach $19.75 in the next twelve months. This suggests a possible upside of 157.2% from the stock's current price.
View analysts price targets for ATXS
or view top-rated stocks among Wall Street analysts.

How have ATXS shares performed in 2023?

Astria Therapeutics' stock was trading at $14.89 at the start of the year. Since then, ATXS stock has decreased by 48.4% and is now trading at $7.68.
View the best growth stocks for 2023 here
.

When is Astria Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our ATXS earnings forecast
.

How were Astria Therapeutics' earnings last quarter?

Astria Therapeutics, Inc. (NASDAQ:ATXS) posted its quarterly earnings data on Monday, November, 13th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.12.

When did Astria Therapeutics' stock split?

Shares of Astria Therapeutics reverse split on the morning of Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of Astria Therapeutics?

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATXS) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -